Oncology Pulse Survey Results

Slideshow

Last month we asked our readers: If you were to start your career again, would you still choose oncology, would you pick a different specialty, or would you perhaps not choose a career in medicine at all? Here are the results.

Recent Videos
Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.
4 experts are featured in this series.
3 experts in this video
Related Content
All patients who received HT-001 in the phase 2a CLEER-001 trial showed significant skin toxicity improvements by 6 weeks.

Topical Gel Significantly Improves EGFR Inhibitor-Related Skin Toxicity

Russ Conroy
January 11th 2025
Article

All patients who received HT-001 in the phase 2a CLEER-001 trial showed significant skin toxicity improvements by 6 weeks.

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

Rachel A. Millstein, PhD, MHS;Loren Winters, NP;Amy Comander, MD
January 6th 2025
Podcast

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Efficacy findings reveal that the phase 3 ARES study evaluating MaaT013 met its primary end point of gastrointestinal overall response rate.

MaaT013 Elicits Durable Responses in Acute Graft-vs-Host Disease

Roman Fabbricatore
January 10th 2025
Article
Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Determining Suitable Radioligand Therapy Use in Neuroendocrine Tumors

Natasha Bahri, MD, MS;Daneng Li, MD
December 30th 2024
Podcast

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Elinzanetant Reduces The Frequency of Hot Flashes in HR+ Breast Cancer

Elinzanetant Reduces The Frequency of Hot Flashes in HR+ Breast Cancer

Tim Cortese
January 10th 2025
Article

Elinzanetant met all primary and secondary end points when compared with placebo in patients with HR-positive breast cancer in the phase 3 OASIS-4 trial.

Phase 1 data support the fast track designation for invikafusp alfa in advanced colorectal cancer with high tumor mutational burden.

Invikafusp Alfa Earns FDA Fast Track Designation in Locally Advanced CRC

Russ Conroy
January 10th 2025
Article

Phase 1 data support the fast track designation for invikafusp alfa in advanced colorectal cancer with high tumor mutational burden.